Skip to main content
. 2016 Feb 4;114(4):444–453. doi: 10.1038/bjc.2015.450

Figure 3.

Figure 3

Kaplan–Meier curves of patient survival according to cytoplasmic eukaryotic translation initiation factor 4E and cytoplasmic and nuclear phospho-eIF4E expression in melanocytic histopathologic subtypes. Significant differences in survival were not found with nuclear eIF4E. Cutoff values chosen a priori were the 75th percentile of each marker. (A) Patients with any form of melanoma who have at or above the 75th percentile of cytoplasmic eIF4E expression have reduced survival. (B) Patients with NM or MM who have at or above the 75th percentile of cytoplasmic eIF4E expression have a reduced survival trend. (C) Patients with any form of melanoma who have at or above the 75th percentile of nuclear eIF4E expression do not have reduced survival. (D) Patients with NM or MM who have at or above the 75th percentile of nuclear eIF4E expression do not have reduced survival. (E) Patients with any form of melanoma who have at or above the 75th percentile of cytoplasmic phospho-eIF4E expression have reduced survival. (F) Patients with NM or MM who have at or above the 75th percentile of cytoplasmic phospho-eIF4E expression have reduced survival. (G) Patients with any form of melanoma who have at or above the 75th percentile of nuclear phospho-eIF4E expression have reduced survival. (H) Patients with NM or MM who have at or above the 75th percentile of nuclear phospho-eIF4E expression have reduced survival.